DDInter783 DDInter1676
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Fosphenytoin {u} (Compound) resembles {v} (Compound) Modafinil
Fosphenytoin {u} (Compound) resembles {v} (Compound) Methylphenobarbital
Fosphenytoin {u} (Compound) treats {v} (Disease) epilepsy syndrome
Fosphenytoin {u} (Compound) binds {v} (Gene) CYP2C9
Fosphenytoin {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Central Nervous System Disorganized Electrical Activity
Fosphenytoin {u} (Compound) causes {v} (Side Effect) Encephalopathy
Fosphenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Fosphenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Fosphenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Fosphenytoin {u} may lead to a major life threatening interaction when taken with {v} Apremilast
Fosphenytoin (Compound) resembles Modafinil (Compound)
Fosphenytoin (Compound) resembles Methylphenobarbital (Compound)
Fosphenytoin (Compound) treats epilepsy syndrome (Disease)
Fosphenytoin (Compound) binds CYP2C9 (Gene)
Fosphenytoin (Compound) is included by Decreased Central Nervous System Disorganized Electrical Activity (Pharmacologic Class)
Fosphenytoin (Compound) causes Encephalopathy (Side Effect)
Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Fosphenytoin may lead to a major life threatening interaction when taken with Apremilast